Claims for Patent: 7,846,428

Summary for Patent: 7,846,428

Title:	Articular cartilage gene therapy with recombinant vector encoding BMP-7
Abstract:	The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intra-articular administration of the recombinant vectors and pharmaceutical compositions of the invention.
Inventor(s):	Fisher; Laurent Bernard (Sainte Foy les Lyon, FR)
Assignee:	Merial Limited (Duluth, GA)
Application Number:	11/867,919
Patent Claims:	1. A method of treating a mammalian subject suffering from osteoarthritis, comprising administering intra-articularly to said mammalian subject a therapeutically effective amount of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle and recombinant adenovirus vectors comprising a polynucleotide encoding a BMP-7 polypeptide having the sequence as set forth in SEQ ID NO: 3 operatively linked to a promoter. 2. The method of claim 1, wherein the BMP-7 polynucleotide has the sequence as set forth in SEQ ID NO: 2. 3. The method according to claim 1, or 2, wherein the recombinant adenovirus vectors are human adenoviruses. 4. The method according to claim 3, wherein the human adenoviruses are human adenoviruses type 5 (hAd5). 5. The method according to claim 4, wherein the human adenoviruses type 5 (hAd5) are PEGylated. 6. The method according to claim 1, or 2, wherein the recombinant adenovirus vectors are canine adenoviruses. 7. The method according to claim 6, wherein the canine adenoviruses are canine adenoviruses type 2 (CAV2). 8. The method according to claim 1, or 2, wherein the mammalian subject is selected from the group consisting of human, canidae, equidae and felidae. 9. The method according to claim 1, or 2, wherein the mammalian subject is a dog, a bitch or a puppy. 10. The method according to claim 1, or 2, wherein the mammalian subject is a cat or a kitten. 11. The method according to claim 1, or 2, wherein the mammalian subject is a horse, a mare or a foal. 12. The method according to claim 1, or 2, wherein the promoter is selected from the group consisting of a CMV IE promoter, a RSV promoter, an HSV-1 TK promoter, a SV40 early promoter, a SV40 late promoter, an adenovirus major late promoter, a phosphoglycerate kinase gene promoter, a metallothionein gene promoter, an .alpha.-1 antitrypsin gene promoter, an albumin gene promoter, a collagenase gene promoter, an elastase I gene promoter, a .beta.-actin gene promoter, a .beta.-globin gene promoter, a .gamma.-globin gene promoter, an .alpha.-fetoprotein gene promoter, and a muscle creatine kinase gene promoter.

Details for Patent 7,846,428

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29